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Meta-analysis is an increasingly popular tool for combiningmultiple different genome-wide association studies (GWASs) in a single aggre-
gate analysis in order to identify associations with very small effect sizes. Because the data of a meta-analysis can be heterogeneous, refer-
ring to the differences in effect sizes between the collected studies, what is often done in the literature is to apply both the fixed-effects
model (FE)under anassumptionof the sameeffect sizebetweenstudies and the random-effectsmodel (RE)underanassumptionofvarying
effect size between studies. However, surprisingly, RE gives less significant p values than FE at variants that actually show varying effect
sizes between studies. This is ironic because RE is designed specifically for the case in which there is heterogeneity. As a result, usually,
RE does not discover any associations that FE did not discover. In this paper, we show that the underlying reason for this phenomenon
is that RE implicitly assumes a markedly conservative null-hypothesis model, and we present a new random-effects model that relaxes
the conservative assumption. Unlike the traditional RE, the newmethod is shown to achieve higher statistical power than FE when there
is heterogeneity, indicating that the new method has practical utility for discovering associations in the meta-analysis of GWASs.Introduction
Genome-wide association studies (GWASs) are an effective
means of detecting associations between a genetic variant
and traits.1 AlthoughGWASshave identifiedmany loci asso-
ciated with diseases, those identified loci account for only
a small fraction of the genetic contribution to the disease.2
The remaining contribution can be accounted for by loci
with very small effect sizes, so small that tens of thousands
of samples are needed if they are to be identified.3 One can
design and conduct a single study collecting such a large
sample, but it will be very costly. A practical alternative is
to combine numerous studies that have already been per-
formed or that are being performed in a single aggregate
analysis calledameta-analysis.4–6Recently, several large-scale
meta-analyses have been performed for diseases including
type 1 diabetes,7 type 2 diabetes,8–10 bipolar disorder,11
Crohn disease,12 and rheumatoid arthritis13 and have
identified associations not revealed in the single studies.
An intrinsic difficulty in conducting a meta-analysis is
choosing which studies to include. Ideally, one would
collect as many studies as possible to increase the sample
size. However, the decision is not always simple because
sometimes the studies differ enough that onewould suspect
that the effect size of the associationwould not be the same
between studies. For example, if the populations or the
environmental factors are substantially different between
studies, there is a possibility that the strength of the associ-
ation is affected by those factors.14,15 If the effect size of the
association varies between studies, we refer to this phenom-
enon as between-study heterogeneity or heterogeneity.16–19
The way in which one optimally designs and analyzes
a meta-analytic study is critically dependent on the
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only collect studies that are highly similar to each other.
Therefore, the sample size might not be maximized, but
the heterogeneity in the data will be minimized. The
commonly applied method of analyzing a collection of
studies for which the effect sizes are expected to be similar
is the fixed-effects model (FE) under an assumption of the
same effect size between studies.4,20,21 Instead, if one
decides to allow some heterogeneity in the data, one can
collect a greater number of studies to maximize the sample
size. The commonly applied method of analyzing a collec-
tion of studies for which the effect sizes are expected to
vary is the random-effects model (RE), explicitly modeling
the heterogeneity.16,18,22,23 In practice, researchers often
apply both FE and RE.24,25 This way, they can discover
the maximum number of associations and compare the
results of the two methods; such a comparison might
help in the interpretation of the results.
A surprising phenomenon that caught our attention
with regard to meta-analysis is that when one applies
both FE and RE to detect associations in the dataset, RE
gives substantially less significant p values than FE at
variants that actually show varying effect sizes between
studies. This is ironic because RE is designed specifically
for the case in which there is heterogeneity. Because
RE gives the same p value as FE at markers showing no
heterogeneity, RE rarely, if at all, gives a more significant
p value than FE at any marker. Therefore, all associations
identified by RE are usually already identified by FE. We
verify this phenomenon through simulations. Because FE
is not optimized for the situation in which heterogeneity
exists and because RE finds no additional associations,
the causal variants showing high between-study heteroge-
neity might not be discovered by either method.Angeles, CA, USA; 2Department of Computer Science and Department of
Genetics. All rights reserved.
2011
In this paper, we show that the underlying reason for
this phenomenon is that RE implicitly assumes a markedly
conservative null-hypothesis model. The analysis in RE is
a two-step procedure extending the traditional estimation
of effect size to hypothesis testing. First, one estimates the
effect size and its confidence interval by taking heteroge-
neity into account.16,17,26,27 Second, the effect size is
normalized into a z score, which is translated into the p
value. We show that this second step is equivalent to
assuming heterogeneity under the null hypothesis.
However, there should not be heterogeneity under the
null hypothesis of no associations because the effect sizes
are all exactly zero. We find that this implicit assumption
of the method makes the p values overly conservative.
We propose a random-effects model that relaxes the
conservative assumption in hypothesis testing. Our
approach estimates the effect size and its confidence
interval in the same way that the traditional RE approach
does. However, instead of calculating a z score as is done
in traditional RE, we apply a likelihood-ratio test and
assume no heterogeneity under the null hypothesis. In
essence, we are separating the hypothesis testing from
the effect size estimation by informing the method that
the existence of the heterogeneity is dependent on the
hypothesis. By taking advantage of this information, the
new method, unlike traditional RE, achieves higher statis-
tical significance than FE if there is heterogeneity. Our
simulations show that the new approach effectively
acquires high statistical power under various types of
heterogeneity, including when the linkage disequilbrium
structures are different between studies.28,29 Applying the
method to the real datasets of type 2 diabetes9 and Crohn
disease12 shows that the method can have practical utility
for finding additional associations in the current meta-
analyses of GWASs.
The new method has several interesting characteristics.
First, the new method is closely related to existing
approaches in the meta-analysis. The statistic consists of
a part corresponding to the average effect size, equivalent
to FE, and a part corresponding to heterogeneity, asymp-
totically equivalent to Cochran’s Q.16 This shows that
heterogeneity as well as effect size contributes to the
discovery of associations in our method. Second, the
statistic asymptotically follows a mixture of c2 distribu-
tions,30 and therefore the p value can be efficiently calcu-
lated. Third, although the new method is more sensitive
to confounding than previous methods, a simple proce-
dure similar to genomic control31 can reduce the effect of
confounding.Material and Methods
Heterogeneity
If there exists actual genetic effect but the effect size level varies
between studies, we refer to this phenomenon as heterogeneity.16
A simple example of heterogeneity is when the populations are
different between studies and the population-specific variationThe Ameaffects the pathways of disease and thus results in different effect
sizes.14,15 However, heterogeneity can also occur when the effect
size is the same but the linkage disequilibrium structures are
different between studies.28,29 In this case, the virtual or observed
effect sizes can vary at the markers as described below.
Because we define the heterogeneity as the difference in effect
sizes, under the null hypothesis of no associations, there should
be no heterogeneity. If there exists no genetic effect but we observe
unexpected variation in the observed effect size, as can be the case
for population structure, we will call it confounding and treat it
separately.31,32
LD Can Cause Heterogeneity
Assume N/2 cases and N/2 controls. Let p be the frequency of the
causal variant having odds ratio g. If we assume a small disease
prevalence, the expected frequency in controls and cases is
pzp (1)
pþz
g p
ðg 1Þpþ 1: (2)
If g is relative risk, Equation 2 is an exact equality. The usual z
score statistic is
S ¼ bpþ  bpﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2bp51 bp5Nq
where p5 ¼ ðpþ þ pÞ=2 and the hats (^) denote observed values. S
followsNðl ﬃﬃﬃﬃNp ;1Þ where
l
ﬃﬃﬃﬃ
N
p
¼ p
þ  pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p5ð1 p5Þ=Np
is the noncentrality parameter.33
Now, assume that we instead collect a marker whose
frequency is similar to that of the causal variant, with which it
has a correlation coefficient r. Pritchard and Przeworski34 show
that the noncentrality parameter at the marker (lm
ﬃﬃﬃﬃ
N
p
) is approx-
imately rl
ﬃﬃﬃﬃ
N
p
. The subscript m denotes that the values are for the
marker.
Thus, we can solve the equation
pþm  pmﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p5m

1 p5m

N
q ¼ r pþ  pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p5ð1 p5Þ=Np
to obtain the virtual odds ratio gm at the marker. By further
assuming that
p5ð1 p5Þzp5m

1 p5m

;
we find that gm is approximately
gmz
ððg 1Þp gþ 1Þr þ ð1 gÞp 1
ðg 1Þpr þ ð1 gÞp 1 :
Table 1 describes the pattern by which gm varies depending on g
and r. Note that if log g ¼ 0 (no genetic effect), log gm is also 0. In
other words, there is no heterogeneity under the null hypothesis.
Traditional FE and RE Approaches
FE Approach
FE assumes that the magnitude of the effect size is the same,
or fixed, across the studies.20,21 The two widely used statistics
are the inverse-variance-weighted effect-size estimate35 and
the weighted sum of z-scores.4 Let X1;.;XC be the effect-sizerican Journal of Human Genetics 88, 586–598, May 13, 2011 587
Table 1. Pattern of Virtual-Effect Size under Various LD
Conditions
Effect at
Causal SNP
LD between Causal
SNP and Marker
Virtual Effect
at Marker SNP
b ¼ 0 (no effect) – bm ¼ 0 (no effect)
b > 0 r ¼ 1.0 (perfect LD) bm ¼ b (same effect)
b > 0 r < 1.0 (imperfect LD) bm < b (smaller effect)
b > 0 r ¼ 0 (no LD) bm ¼ 0 (no effect)
b > 0 r < 0 (negative LD) bm < 0 (effect in
opposite direction)
b is the effect size at the causal SNP, and bm is the virtual effect size observed
at the marker. The LD measure is r, the Pearson correlation coefficient.estimates, such as the log odds ratios or regression coefficients, in
C independent studies. Usually, X1;.;XC follow normal distribu-
tions if the sample sizes in each study are sufficiently large. Let
SEðXiÞ be the standard error of Xi and Vi ¼ SEðXiÞ2. Although Vi
is estimated from the data, it is a common practice to consider it
as a true value in the analysis. Let Wi ¼ V1i be the inverse vari-
ance. The inverse-variance-weighted effect-size estimator is
X ¼
P
WiXiP
Wi
: (3)
It follows that the standard error of X is SEðXÞ ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPWip 1.
Because X will also follow a normal distribution, we can construct
a statistic
ZFE ¼ X
SEðXÞ ¼
P
WiXiﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
Wi
p ;
which follows Nð0;1Þ under the null hypothesis of no associa-
tions. The p value of the association if we assume a two-sided
test will then be
pFE ¼ 2Fð  jZFE j Þ;
whereF is the cumulative density function of the standard normal
distribution.
The p value can also be obtained with z scores. Let Z1;.;ZC be
the z scores. A weighted sum of z scores is
ZWS ¼
P ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Nipi

1 pi
q
i
ZiﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
Nipi

1 pi
q :
Ni is the so-called effective sample size of study i and can be
approximated to 2Nþi N

i =ðNþi þ Ni Þ when Nþi =2 cases and Ni =2
controls are in study i. pi is the minor allele frequency of the
marker in study i. The p value is then
pWS ¼ 2Fð  jZWS j Þ:
pFE and pWS are usually very similar.
36,37
Usually, theweights of only
ﬃﬃﬃﬃﬃ
Ni
p
instead of
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Nipið1 piÞ
p
are used
under the assumption that the frequencies are similar.4However, in
general, explicitly employing frequency information in theweights
can be the most powerful. One can easily demonstrate this in the
case of binary alleles and binary traits by showing the following
three things: (1) the Mantel-Haenszel test21 is the uniformly most
powerful unbiased test, as shown by Birch,38 (2) the inverse-
variance weighted odds ratio is approximately equivalent to the588 The American Journal of Human Genetics 88, 586–598, May 13,Mantel-Haenszel, and (3) the weighted sum of z scores is approxi-
mately equivalent to the inverse-variance weighted log odds ratio
only when the weights include the frequency information.
RE Approach
On the other hand, the RE approach assumes that the true value of
the effect size of each study is sampled from a probability distribu-
tion having variance t2.16 The between-study variance t2 is esti-
mated by various approaches,26,27,39–41 such as the method of
moments,16 the method of maximum likelihood,42 and the
method of restricted maximum likelihood.17 Given the estimated
between-study variance bt2, the effect size estimate is calculated
similarly to Equation 3 but with the additional variance term ac-
counted for, as follows:
X
 ¼
P
W1i þ bt21XiP
W1i þ bt21 :
It follows that SEðXÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPðW1i þ bt2Þ1q 1. The test statistic
can be similarly constructed as
ZRE ¼ X

SEðXÞ; (4)
and the p value is
pRE ¼ 2Fð  jZRE j Þ:
Note that if the frequency and sample size are equal between
studies (W1 ¼. ¼ WC), then X ¼ X. However, because
SEðXÞR SEðXÞ, we obtain pRERpFE. That is, it is easily shown
analytically that RE never gives a more significant p value than
FE if the sample size is equal.
RE Assumes Heterogeneity under the Null Hypothesis
To show that RE implicitly assumes heterogeneity under the
null hypothesis, we describe FE and RE as likelihood ratio tests.
In a typical meta-analysis, the analysis is a two-step procedure:
(1) the result of each study is summarized in a statistic (e.g.,
effect-size estimate), and (2) the statistics of the multiple studies
are combined. Thus, each statistic can be considered as a single
observation. Here we consider the likelihood of these observations
rather than of the raw data. We make an assumption that each
statistic follows a normal distribution; such an assumption is
usually acceptable in GWASs because of the large sample size.
Let X1;.;XC be the effect-size estimates of C studies. Let Vi and
Wi be the variance and inverse variance of Xi. Consider the likeli-
hood ratio test under the fixed-effects model. Let L0 and L1 be the
likelihood under the null and alternative hypotheses, respectively.
Then,
L0 ¼
Y
i
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pVi
p exp

 X
2
i
2Vi
	
L1 ¼
Y
i
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pVi
p exp
 
 ðXi  mÞ
2
2Vi
!
;
where m is the unknown true mean effect size. The test is whether
ms0. Solving vL1=vm ¼ 0 shows that themaximum likelihood esti-
mate of m is
bm ¼ X ¼PWiXiP
Wi
:
Thus, the likelihood ratio test statistic for the composite hypoth-
esis is2011
2logðlÞ ¼ 2log

sup L0
sup L1
	¼P
i
X2i
Vi

X
i
ðXi  bmÞ2
Vi
¼P
i
2XiXX2
Vi
¼ 2XPWiXi X2PWi
¼ XPWiXi
¼ Z2FE;
(5)
showing that this likelihood ratio test is equivalent to FE.
Similarly, RE can be described as a likelihood ratio test. The
current RE framework estimates the between-study variance t2
first and subsequently uses the value in the statistical test. Letbt2 be the between-study variance as estimated by any method.
Consider a likelihood ratio test assuming the same bt2 as a constant
under both the null and the alternative hypotheses. The likeli-
hoods are
L0 ¼
Y
i
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p

Vi þ bt2r exp
 
 X
2
i
2

Vi þ bt2
!
L1 ¼
Y
i
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p

Vi þ bt2r exp
 
 ðXi  mÞ
2
2

Vi þ bt2
!
:
The maximum likelihood estimate of m is
bm ¼ X ¼P

W1i þ bt21XiP
W1i þ bt21 :
Thus, the likelihood ratio test statistic is
2logðlÞ ¼
X
i
2XiX
 X2
Vi þ bt2 ¼ Z2RE;
showing that this likelihood ratio test is equivalent to RE.
This conversely shows that the current RE calculates heteroge-
neity under the alternative hypothesis and then implicitly
assumes the same heterogeneity under the null hypothesis, which
we find to be the cause of the conservative nature of the method.New RE Approach
We propose a new RE that assumes there is no heterogeneity under
the null hypothesis. We employ the same likelihood ratio frame-
work that considers each statistic as a single observation. Because
we assume there is no heterogeneity under the null hypothesis,
m ¼ 0 and t2 ¼ 0 under the null hypothesis. The likelihoods are
then
L0 ¼
Q
i
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pVi
p exp

 X
2
i
2Vi
	
L1 ¼
Q
i
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pðVi þ t2Þ
p exp   ðXi  mÞ2
2ðVi þ t2Þ
!
Themaximum likelihood estimates bm and bt2 can be found by an
iterative procedure suggested by Hardy and Thompson.42 Specifi-The Amecally, given the current estimate bmðnÞ and bt2ðnÞ, the next estimates
are obtained by the formula
bmðnþ1Þ ¼
P Xi
Vi þ bt2ðnÞP 1
Vi þ bt2ðnÞ
bt2ðnþ1Þ ¼
PXi  bmðnþ1Þ2Vi
Vi þ bt2ðnÞ2P 1
Vi þ bt2ðnÞ2
:
Once we find the maximum likelihood estimates bm and bt2, the
likelihood ratio test statistic can be built as follows:
SNew ¼ 2logðlÞ ¼
X
log

Vi
Vi þ bt2
	
þ
XX2i
Vi

X ðXi  bmÞ2
Vi þ bt2 : (6)
The statistical significance of this statistic can be assessed in
various ways. The naive way is to permute the data within
each study to obtain the null distribution. A more efficient
approach is to sample Xi from Nð0;ViÞ on the basis of the
normality assumption. However, for highly significant p values,
sampling approaches can be inefficient. An even more efficient
approach is to use asymptotic distribution. Because m is unre-
stricted and t2 is restricted to be non-negative in the parameter
space, m corresponds to a normal distribution and t2 corresponds
to a half of normal distribution in the orthonormal-transformed
space. Therefore, the statistic asymptotically follows an equal
mixture of 1 degree of freedom (df) c2 distribution and 2 df c2
distribution. See Self and Liang30 for more details. However,
the asymptotic result only holds when the number of studies is
large. Given only a few studies, the asymptotic p value is overly
conservative because of the tail of asymptotic distribution is
thicker than that of the true distribution at the genome-wide
threshold. This phenomenon is similar to that observed by
Han et al.33 in the context of correcting p values for multiple
hypotheses.
Instead, we provide tabulated values. For each possible number
of studies from 2 to 50, we generate 1010 null statistics to construct
the p value tables that provide p values with reasonable accuracy
up to 108. For p values more significant than 108, we use the
asymptotic p value corrected by the ratio between the asymptotic
p value and the true p value estimated at 108. Because the ratio
keeps decreasing with significance level, using the ratio estimated
at 108 will make the resulting p value slightly conservative but
not anti-conservative. The tabulated values are built on an
assumption of equal sample size between studies. Because the
discrepancy between the asymptotic p value and the true p value
is usually greater for unequal sample size than for equal sample
size, using our tabulated values for unequal sample size case will
make the resulting p value slightly conservative but not anti-
conservative.
Relationship to FE and Cochran’s Q Statistic
Our new method has the following relationship to previous
methods. The statistic in Equation 4 can be decomposed into
two parts,rican Journal of Human Genetics 88, 586–598, May 13, 2011 589
SNew ¼
P
log

Vi
Vi þ bt2
	
þ
XX2i
Vi

X ðXi  bmÞ2
Vi þ bt2
¼
(XX2i
Vi

XXi  bm02
Vi
)
þ
(X
log

Vi
Vi þ bt2
	
þ
XXi  bm02
Vi

X ðXi  bmÞ2
Vi þ bt2
)
¼ SFE þ SHet
where bm0 is the maximum likelihood estimate of m under the
restriction t2 ¼ 0, which may be different from bm.
The first part of the statistic, SFE, is equal to the FE statistic Z
2
FE
shown in Equation 5. This is the contribution of the mean effect.
The second part of the statistic, SHet , is equal to the statistic that we
would obtain if we test t2s0. That is, this is the test statistic
testing for heterogeneity. This shows that heterogeneity can actu-
ally help to find associations in our method. SFE asymptotically
follows a 1 df c2 distribution, and SHet asymptotically follows an
equal mixture of zero and 1 df c2.30
SHet tests the same hypothesis as the Cochran’s Q statistic.
16 In
the usual case, Q should be preferred because SHet requires a large
number of studies for an asymptotic result. However, asymptoti-
cally they should give the same results.
This decomposability of the statistic can help interpretation
because we can assess what proportion of the statistic is due to
the mean effect and what proportion is due to the heterogeneity.
Correcting for Confounding
An advantage of the decomposability of the statistic is that one
can apply a simple procedure similar to genomic control31 to
each part to correct for confounding. Because the first part, SFE,
is exactly Z2FE, applying genomic control is straightforward. For
the second part, SHet , one can apply genomic control by assessing
the median value under the restriction SHet > 0 and then
comparing it to the expected value under the null hypothesis.
We also provide the tabulated null median values of SHet for
various numbers of studies.
Given the inflation factors lFE and lHet calculated for the first
and the second parts separately, the corrected statistic will be
S0New ¼ SFE=lFE þ SHet=lHet :
Interpretation and Prioritization
In the usual meta-analysis where one collects similar studies and
expects the common effect of the variant, the results found by
FE should be the top priority, but the results found by our method
can also suggest interesting regions. As suggested by previous
studies,18,22 an association showing large heterogeneity requires
careful investigation of the cause of heterogeneity. If the heteroge-
neity is caused by the between-study difference in the underlying
pathways of disease, a correct identification of the cause of hetero-
geneity might help researchers to understand the disease.
Note that the effect-size estimate and its confidence interval in
our new RE remain the same as those in the current RE. This is
because we changed the assumption only under the null hypoth-
esis, whereas estimating effect size and its confidence interval can
be thought of as happening under the alternative hypothesis.
Note that an extremely wide confidence interval might not always
correspond to a statistically nonsignificant result in our framework.Simulation Framework
In the Results, we use the following simulation approach. Under
the assumption of a minor allele frequency, an odds ratio, and590 The American Journal of Human Genetics 88, 586–598, May 13,the number of individuals of Nþ=2 cases and N=2 controls,
a straightforward simulation approach is to sample Nþ alleles for
cases and N alleles for controls according to the probabilities
given in Equations 1 and 2. However, because we perform exten-
sive simulations in which we assume thousands of individuals,
we use an approximation approach that samples the minor-allele
count from a normal distribution and rounds it to the nearest
integer.Results
Motivating Observation: RE Never Achieves Higher
Statistical Significance than FE in Practice
We first describe our motivating observation that the
current RE approach never achieves higher statistical
significance than the FE approach in practice. In the Mate-
rial and Methods, we have already analytically shown that
if the sample size is equal between studies, the p value of RE
(pRE) cannot be more significant than the p value of FE
(pFE). Therefore, our interest is in the situation in which
the sample size is unequal.
We assume five independent studies with unequal
sample sizes of 400, 800, 1200, 1600, and 2000. Through
all experiments, the sample size refers to the combined
number of cases and controls in a balanced case-control
study, and a population minor-allele frequency of 0.3 is
assumed. Note that the specific values of the parameters
are not the major factor affecting the results. For example,
if we increase the sample size and decrease the minor-allele
frequency or the assumed effect size, we will have the
similar results (data not shown).
Our goal is to simulate every possible situation with
a large number of random simulations to examine in
which situation RE gives more significant results than FE.
Because FE is optimal if there is no heterogeneity, we
assume heterogeneity and randomly sample odds ratios
of the studies from a probability distribution. We assume
a mean odds ratio of g ¼ 1:1 and sample the log odds ratio
of each study fromNðlogðgÞ; logðgÞ2Þ. This is large hetero-
geneity; with a high chance of Fð1:0Þz15:9, the direc-
tion of the effect will even change.
On the basis of the sampled odds ratios, we sample the
cases and controls for each study. Then we calculate pFE
and pRE by using the inverse-variance weighted-effect-size
approach. In calculating pRE, we estimate bt2 by themethod
of moments of DerSimonian and Laird.16 If at least one of
pFE and pRE is significant (p%0:05), we accept the study.
Otherwise, we repeat the procedure. We construct one
million sets of meta-analyses.
Figure 1 shows that our one million trials cover a variety
of situations. Figure 1A shows that the p values (pFE) are
distributed in a wide range of significance levels covering
the level above the genome-wide threshold. Figure 1B
shows the distribution of the I2 statistic, which is a metric
of the amount of heterogeneity.17 Except for the peak
at the zero, I2 is distributed evenly from low to high.
Figure 1C shows the distribution of the correlation2011
Figure 1. Our One Million Trial Simulations Comparing p Values of FE and RE
We assume five studies of sample sizes of 400, 800, 1200, 1600, and 2000. (A), (B), and (C) show that our simulations cover a wide range
of p values (pFE), heterogeneity (I
2), and correlations between the effect size and sample size, respectively. (D) shows that RE never gives
a more significant p value than FE in our simulations.between the sample size and the observed effect size.
Because RE assigns a greater weight to smaller studies, it
will be favorable to RE if smaller studies show larger effect
sizes.5 Figure 1C shows that in half of the simulations, the
correlation is negative, and therefore the situation is favor-
able to RE.
Table 2 shows that RE gives a more conservative p value
than FE in 75% of trials and that it gives an equally signif-
icant p value in 25% of trials. However, surprisingly, in
none of the trials does RE give a more significant p value
than FE (Figure 1D). That is, we observe an extreme
phenomenon that RE never achieves higher statistical
significance than FE in our extensive random simulations.Table 2. Comparison of p Values of FE and RE in One Million
Random Simulations
pFE< pRE pFE¼ pRE pFE> pRE
747,443 252,557 0
Our simulations are designed to explore many different situations, such as
differing p value levels or heterogeneity levels. We assume five studies of
sample sizes of 400, 800, 1200, 1600, and 2000.
The AmeWe can explain this phenomenon at the statistics level.
In order to obtain pRE < pFE, smaller studies must show
larger effect sizes so that RE can re-weight the studies. For
the weights to drastically change in such a way, the esti-
mated between-study variance bt2 has to be large. However,
if bt2 is large, the denominator of ZRE in Equation 4 also
increases, diminishing the statistical significance. It seems
that the significance-decreasing effect of the additional
variance (bt2) is always greater than the significance-
increasing effect of re-weighting in practice.
This result suggests that the current RE might not be
suitable for discovering candidate associations in GWAS
meta-analysis, indicating the need for a new method.False-Positive Rate
At threshold a ¼ 0:05
We examine the false-positive rate of FE, RE, and the new
RE method (new RE). We assume the null hypothesis of
no associations and assume that there is no confounding.
Because the effect sizes are all exactly zero, there is no
heterogeneity. We construct five studies with an equal
sample size of 1,000 and calculate the meta-analysisrican Journal of Human Genetics 88, 586–598, May 13, 2011 591
Table 3. False-Positive Rate of FE, RE, and the New RE at Threshold
a ¼ 0.05
# Studies Sample Size FE RE New RE
3 equal 0.0506 0.0381 0.0501
3 unequal 0.0504 0.0368 0.0488
5 equal 0.0493 0.0370 0.0496
5 unequal 0.0495 0.0364 0.0490
10 equal 0.0504 0.0394 0.0503
10 unequal 0.0495 0.0375 0.0484
20 equal 0.0499 0.0406 0.0497
20 unequal 0.0496 0.0395 0.0485
A sample size of 1000 is assumed when sample sizes are equal. For unequal
sample sizes, we use evenly spaced values such as 100, 200, ., 2000 for 20
studies.
Table 4. False-Positive Rate of FE, RE, and the New RE at
Thresholds of Increasing Significance
Threshold
a FE RE New RE
0.05 4.98 3 102 (1.00) 3.75 3 102 (0.75) 4.98 3 102 (1.00)
1 3 102 9.94 3 103 (0.99) 7.03 3 103 (0.70) 9.93 3 103 (0.99)
1 3 103 9.90 3 104 (0.99) 6.67 3 104 (0.67) 9.88 3 104 (0.99)
1 3 104 9.78 3 105 (0.98) 6.36 3 105 (0.64) 9.80 3 105 (0.98)
1 3 105 1.03 3 105 (1.03) 6.65 3 106 (0.67) 1.02 3 105 (1.02)
1 3 106 9.20 3 107 (0.92) 5.70 3 107 (0.57) 8.90 3 107 (0.89)
The ratio between the false-positive rate and the threshold a is shown in the
parentheses. The estimates are obtained from 100 million null panels. Five
studies of equal sample size 1000 are assumed.p value. We repeat this 100,000 times and estimate the
false-positive rate as the proportion of the repeats whose
p value is %0:05. We also differ the number of studies to
3, 10, and 20 studies. When we assume unequal sample
sizes, we use evenly spaced values from 0 to 2000, such
as 100, 200, ., 2000 for 20 studies. For new RE, we use
the tabulated values to assess p values.
Table 3 shows that the false-positive rate of FE is
constantly accurate regardless of the number of studies.
RE is conservative and has a false-positive rate smaller
than 0.05. This is because the between-study variance bt2
is often estimated as non-zero because of the stochastic
nature of the sampling. As the number of studies increases,
the conservative nature is reduced because more studies
provide accurate information that the true t2 is zero.
New RE shows accurate false-positive rates. New RE is
slightly conservative when the sample size is unequal
because, as explained in the Material and Methods, the
tabulated values are constructed under an assumption of
equal sample size. However, the false-positive rate is very
close to the desired value even in that case.
At More Stringent Thresholds
It is often of interest to examine the false-positive rate at
a more stringent threshold close to the genome-wide
threshold. Assuming the same settings for five studies,
we simulate 100 million meta-analyses under the null
hypothesis. With this large number of simulations, we
can estimate the false-positive rate with reasonable accu-
racy for up to a threshold of approximately 106.
Table 4 shows that, at all thresholds that we tested, the
false-positive rates of both FE and new RE are accurately
controlled. On the other hand, RE becomes more conser-
vative as the threshold becomes more significant.
Genome-wide Simulations
In this genome-wide simulation, we examined whether
each of the meta-analysis methods shows a noninflated
QQ plot under the null hypothesis. We simulated a GWAS
meta-analysis of seven studies by using theWellcome Trust592 The American Journal of Human Genetics 88, 586–598, May 13,Case Control Consortium (WTCCC) data.43 We used the
seven case groups of seven diseases as our cases of seven
studies. Then we evenly divided the two groups of
controls, 58C and NBS, one group at a time, into seven
subgroups and used them as our controls. We removed
all SNPs that are significant (p < 5 3 107) either in the
original WTCCC study or in our simulated studies. Thus,
most of the remaining SNPs should have been null. We
also removed the SNPs with no rsIDs, SNPs filtered by
WTCCC QC, and the chromosome 6 SNPs that include
the major histocompatibility complex region. This re-
sulted in 364,035 SNPs, which is still large enough to allow
an examination of the characteristics of the methods.
The WTCCC results43 and previous studies32 show that
there can be a small amount of cryptic relatedness in the
data of WTCCC. The genomic control factor of WTCCC
is slightly more than 1.0, and the QQ plot of each disease
shows a slight inflation at the tail. We were interested in
whether this small confounding affects each method and
by how much.
Figure 2 shows the QQ plots and the genomic control
factors. The QQ plot of FE (Figure 2B) is very similar to the
QQ plot of the single study (Figure 2A), showing that FE is
not sensitive to the confounding. The QQ plot of RE
(Figure 2C) looks completely null. The genomic control
factor (0.86) is below 1.0, showing that RE is conservative.
The QQ plot of new RE (Figure 2D) is more inflated than
that of the single study or other methods. This shows that
our method is more sensitive to the small confounding in
the dataset. To correct for this, we calculate the genomic
control factors for the mean-effect part of the statistic (SFE)
and the heterogeneity part of the statistic (SHet) separately;
these values are 1.04 and 1.11, respectively. After we correct
the calculations with these factors, the inflation is reduced
(Figure 2E). However, our method is still more inflated
than other methods, suggesting that a more sophisticated
method can be developed for a further correction.
Power
We compared the power of FE, RE, and new RE. We used
the similar simulation settings of the five studies of equal2011
Figure 2. QQ Plot of Various Methods in
the Simulated GWAS Meta-Analysis
Involving the WTCCC Data
Lambda denotes the genomic control31
inflation factor.sample size of 1,000. We constructed 10,000 sets to esti-
mate the power as the proportion of the sets whose p value
exceeds a genome-wide threshold 107.
We first assumed that the variability in effect size
induced by between-study heterogeneity follows a normal
distribution.26,41 Starting from no heterogeneity, we grad-
ually increased the between-study variance and examined
how power changes. Specifically, given the mean odds
ratio g, we set the standard deviation of the effect size to
be k logðgÞ, where we change k from 0 to 1. We used
g ¼ 1:3. We also simulated different settings. We assumed
unequal sample sizes and assumed ten studies with an
odds ratio of 1.2. When assuming unequal sample sizes,The American Journal of Humanwe used the sample size of 400,
800, ., 2000 for five studies and
200, 400,., 2000 for ten studies.
Figure 3 shows that, when there
is no between-study heterogeneity, FE
is the most powerful. As the between-
study heterogeneity increases, the
power of FE drops. The power of RE
is always the lowest among the three
methods and drops with the amount
of heterogeneity. The power of new
RE is slightly lower than FE when no
heterogeneity exists. As the between-
study heterogeneity increases, new
RE becomes the most powerful. New
RE starts to outperform FE at a level
of moderate heterogeneity, between
k ¼ 0:3 and k ¼ 0:4. The relative
performance between methods is the
same for all four settings.
Different LD
Although it is usual in the meta-anal-
ysis literature to assume the normal
variability in the effect size, as in
the previous experiment,26,41 there
can be other situations. Here we
assume that the actual effect size
is the same between studies but
that different LD structures induce
different virtual effect sizes at the
marker. Assuming five studies of
equal sample size of 1,000, we varied
the correlation coefficient between
the causal variant and the marker
by the three patterns (cases 1, 2,
and 3 in Table 5). We assumed anodds ratio g ¼ 1.3, 1.5, and 1.7 for cases 1, 2, and 3,
respectively.
Figure 4 shows that, in case 1 under an assumption of no
heterogeneity by LD, FE is the most powerful. In case 2
under an assumption of heterogeneity by LD, our new
RE is the most powerful. In case 3, we assumed larger
heterogeneity by LD and that the direction of the correla-
tion is opposite in some studies. This situation should be
rare, but it is certainly possible. In this case, FE and RE
have low power, whereas our new RE has high power.
When Effects Exist in the Subset of Studies
Here we simulate another situation, in which the genetic
effect of the variant only exists in a subset of the studies.Genetics 88, 586–598, May 13, 2011 593
Figure 3. Power of FE, RE, and Our New
RE Method in a Simulation Varying
Between-Study Heterogeneity
We simulate various settings of the
number of studies and sample size. The x
axis denotes heterogeneity k, where we
simulate the standard deviation of the
effect size (log odds ratio) to be k times
the effect size. We assume the mean odds
ratio of 1.3 for five studies and 1.2 for ten
studies. When we assume equal sample
sizes, we use the sample size of 1000.
When we assume unequal sample sizes,
we use the sample sizes of 400, 800, .,
2000 for five studies and 200, 400, .,
2000 for ten studies.This can happen when the populations are different
between studies and the effect is dependent on the popu-
lation.14,15 Assuming five studies of equal sample size of
1,000, we decreased the number of studies having effect,
CE, from 5 to 2. We use an odds ratio g ¼ 1.3, 1.37, 1.45,
and 1.6 for CE ¼ 5, 4, 3, and 2, respectively. Figure 5 shows
that as the number of studies having an effect decreases,
the power of FE and RE drops. By contrast, our new RE
method achieves high power.
The reason that we increase the odds ratio as the hetero-
geneity increases in this and previous experiments is to
easily compare the power of methods at a moderate power
level. Figure S1 shows a different setting where we assume
a fixed odds ratio of 1.3, which shows decreasing power as
CE decreases, as it should, for each method.Table 5. Correlation Coefficient r between the Causal Variant and
the Marker in Three Different Scenarios Simulating Different LD
Structures between Studies
Study 1 Study 2 Study 3 Study 4 Study 5 Note
Case 1 1.0 1.0 1.0 1.0 1.0 no heterogeneity
by LD
Case 2 1.0 0.8 0.6 0.4 0.2 heterogeneity
by LD
Case 3 1.0 0.8 0.6 0.2 0.6 larger
heterogeneity
by LD
Figure 4. Power of FE
Structures Are Differen
The LD patterns that
Table 5. We assume an
2, and 3, respectively.
five studies.
594 The American Journal of Human Genetics 88, 586–598, May 13, 2011Application to the Type 2 Diabetes Data
We applied our method to the real
data of the meta-analysis of type 2
diabetes by Scott et al.9 The meta-
analysis consists of three different
GWASs, the Finland-United States
Investigation on NIDDM Genetics
(FUSION),9 the Diabetes Genetics
Initiative,10 and the WTCCC.8,43
Although amore recentmeta-analysis
of type 2 diabetes exists,44,45 we used
these data because Ioannidis et al.18
re-analyzed the data to compared FEand RE. In their analysis, Ioannidis et al. emphasize that
the results of FE and RE can be critically different when
heterogeneity exists, and results showing high heteroge-
neity should always be further investigated. However, the, RE, andOur New REMethodwhen the LD
t between Studies
we assume for each case are described in
odds ratio of 1.3, 1.5, and 1.7 for cases 1,
We assume equal sample sizes of 1000 for
Figure 5. Power of FE, RE, and Our New RE when the Number of
Studies Having an Effect Varies
We assume five studies and gradually decrease the number of
studies having an effect from five to two. We assume equal sample
sizes of 1000. We increase the odds ratio as the number of studies
decreases to show the relative performance between methods.
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Figure 6. The Performance of RE andOur NewRE in the Real Da-
taset of Type 2 Diabetes
The relative gain in statistical significance relative to FE is plotted
for each method. We use the meta-analysis data of Scott et al.9phenomenon whereby RE never gives more significant
p value than FE also persists in their analysis.
Table 6 shows that at two SNPs (rs9300039 and
rs8050136) out of ten associated SNPs, our new RE method
achieves the highest statistical significance among all
three methods. In Figure 6, we sort the SNPs by heteroge-
neity (I2) and plot the relative gain in statistical signifi-
cance for both the traditional RE and our new RE compared
to FE. This shows that FE achieves the highest statistical
significance at low heterogeneity but that, as the heteroge-
neity increases, our newmethod achieves higher statistical
significance. In contrast, the traditional RE gives the same
p value as FE when there is no observed heterogeneity and
becomes substantially conservative with heterogeneity. As
a result, the traditional RE does not give a more significant
p value than FE at any SNPs.Table 6. Application of the Three Methods to the Type 2 Diabetes
Meta-Analysis Results of Scott et al.9
SNP I2 FE p Value RE p Value New RE p Value
rs8050136 76.80 1.30 3 1012 1.48 3 102 6.60 3 1013
rs9300039 74.95 4.33 3 107 1.53 3 102 1.83 3 107
rs1801282 47.42 1.72 3 106 3.41 3 104 2.16 3 106
rs7754840 46.44 4.09 3 1011 3.17 3 106 5.69 3 1011
rs13266634 31.60 5.34 3 108 8.68 3 106 7.23 3 108
rs4402960 24.67 8.57 3 1016 6.48 3 1012 1.61 3 1015
rs10811661 0.00 7.76 3 1015 7.76 3 1015 1.41 3 1014
rs1111875 0.00 5.74 3 1010 5.74 3 1010 8.63 3 1010
rs7903146 0.00 1.03 3 1048 1.03 3 1048 3.39 3 1048
rs521911 0.00 6.68 3 1011 6.68 3 1011 1.05 3 1010
The boldface denotes the top p value among three methods.
The AmeBoth of the SNPs at which our new method achieves the
highest statistical significance show high heterogeneity.
Ioannidis et al.18 suggest that the heterogeneity at
rs9300039 might reflect in part the different tag polymor-
phisms used in the other two GWASs, suggesting that the
virtual effect size varies at the marker because of the use
of different markers between studies. Ioannidis et al. also
provide an insightful suggestion that rs8050136 (in FTO)
might be caused by an unaccounted-for effect of obesity
given that it is not significant in the Diabetes Genetics
Initiative study, where the body-mass index is matched
between cases and controls.10 This shows that our new
RE method can be sensitive to unaccounted-for factors,
including confounding.
Note that because in this analysis we used Scott et al.’s
report9 that provides the odds ratios up to two digits after
the decimal point, the actual results will be different from
our results. However, our results suffice to show the relative
performance between methods.
Application to the Crohn Disease Data
We also apply our method to the data of the recent meta-
analysis of Crohn disease of Franke et al.12 This meta-anal-
ysis consists of six different GWASs comprising 6,333 cases
and 15,056 controls and even more samples in the replica-
tion stage. In this study, 39 associated loci are newly iden-
tified, increasing the number of associated loci to 71. We
apply our method to 69 loci, excluding rs694739 and
rs736289, for which detailed allele counts are missing in
that study’s Table S3. We use the data of six GWASs but
exclude the replication samples.
Table 7 shows that at six loci out of 69, our new method
achieves the highest statistical significance among three
methods. See Table S1 for the results for all 69 loci. Again,
the results show that our new RE can achieve higher
statistical significance than FE, whereas the traditionalrican Journal of Human Genetics 88, 586–598, May 13, 2011 595
Table 7. Application of the Three Methods to the Crohn Disease Meta-Analysis Results of Franke et al.12
SNP Chromosome Position FE p Value RE p Value New RE p Value I2
rs4656940 1 159,096,892 1.05 3 106 6.89 3 104 6.91 3 107 57.01
rs3024505 1 205,006,527 7.03 3 109 5.29 3 105 5.49 3 109 46.49
rs780093 2 27,596,107 1.12 3 104 5.95 3 102 2.78 3 105 61.85
rs17309827 6 3,378,317 5.62 3 106 1.00 3 104 4.98 3 106 22.98
rs17293632 15 65,229,650 6.17 3 1013 2.11 3 106 3.41 3 1013 52.11
rs151181 16 28,398,018 3.32 3 1010 3.80 3 106 3.08 3 1010 35.22
The boldface denotes the top p value among threemethods. Only the six SNPs at which new RE achieves the top p value are shown in the table. See Table S1 for all
69 SNPs tested.RE does not provide a more significant p value than FE at
any SNPs.Discussion
We propose a new RE meta-analysis method that achieves
high power when there is heterogeneity. We observe that
the phenomenon whereby the traditional RE gives less
significant p values than FE under heterogeneity occurs
because of its markedly conservative null-hypothesis
model, and we relax the conservative assumption. Applica-
tion to the simulations and real datasets shows that our
new method can have utility for discovering associations
in GWAS meta-analysis.
In essence, the new method is an attempt to separate
hypothesis testing from effect-size estimation. Hypothesis
testing and point estimation are both important but
distinct subjects in statistics.46 The difference is that, in
point estimation, the null hypothesis is not considered,
and therefore it is conceptually equivalent to considering
only the alternative hypothesis. Many of the traditional
meta-analytic studies primarily focus on accurate estima-
tion of the effect size, confidence interval, and heteroge-
neity (t2), which is the point estimation.16,35,42,47 The
traditional RE approach is a naive extension of this frame-
work to hypothesis testing, but this approach turns out to
be conservative in association studies where assuming no
heterogeneity is natural under the null hypothsesis.
Our method assumes no heterogeneity under the null
hypothesis and assumes heterogeneity under the alterna-
tive hypothesis. Higgins et al.39 describe many possible
null and alternative hypotheses that are appropriate
in various situations in meta-analysis, and our method
is one specific combination of a null and an alterna-
tive hypothesis among those. Lebrec et al.48 considered a
similar combination, but our method differs from theirs
in several ways. First, our formulation allows correcting
for population structure, which is crucial in these studies
because the effect of confounding is exaggerated in the
new formulation. Second, we use a more accurate approx-
imation of the statistical significance. Our simulation596 The American Journal of Human Genetics 88, 586–598, May 13,shows that one might lose power by using the asymptoti-
cally calculated p values, which can be conservative in
comparison to this more accurate approximation
(Figure S2).
In the application to the real datasets of type 2 diabetes9
and Crohn disease,12 our method achieves higher statis-
tical significance than FE at some SNPs, whereas the tradi-
tional RE does not. However, this occurred only at a rela-
tively small number of SNPs, two SNPs out of ten for
type 2 diabetes data and six SNPs out of 69 for Crohn
disease data. Themain reason for this small number should
be the low heterogeneity in the overall data, but one
reason might be that we applied our method only to the
FE-uncovered associations that were readily available in
the literature. The causal SNPs with high heterogeneity
might not be discovered by FE and therefore might not
be included in our analysis, which can be revealed by an
application of our method to the whole-genome data.
In our experiments of both simulated and real datasets,
FE always performs better than our method when there is
no heterogeneity. However, Figures 3, 4, and 5 show that
the relative power gain of FE is not very dramatic. This is
in some sense surprising because our method assumes
higher degrees of freedom than FE. Figure S2 shows that
the performance gap is greater if we use the asymptotic
p values. Thus, it seems that our estimation procedure
aimed at obtaining more accurate p values is helping our
method to have comparable power to FE in this situation.
In this paper, we explored many different scenarios of
heterogeneity, including the case in which the effect size
actually varies between studies as well as the case in which
the observed effect size varies because of the different LD
structures. Another scenario in which the observed effect
size can vary in spite of unvarying effect size is that
involving the ‘‘winner’s curse,’’49 which might inflate the
observed effect size in the initial stage in the multi-stage
design. If the effect of this phenomenon is huge, our
method can be useful for detecting such variants, although
the interpretation should distinguish such phenomenon
from the actual heterogeneity of varying effect sizes.
One important challenge in applying our method is
the interpretation. Given the associations with high2011
heterogeneity, a follow-up will always be essential for
understanding the cause of heterogeneity and verifying
the results. The ability to account for the heterogeneity
and carefully investigate the results might allow us to
expand the subject of meta-analysis to a broader area.
The application of our method can extend beyond the
analysis of a single disease to that of multiple diseases
with similar etiology,43 analysis of eQTL data indepen-
dently collected frommultiple tissues, or analysis of mixed
samples with similar phenotypes but multiple causal path-
ways, as in the case of mental diseases.50Supplemental Data
Supplemental Data include one table and two figures and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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